The authors of a review article on the future of ustekinumab biosimilars for treating Crohn disease (CD) discussed key ...

Recent years have seen significant advancements in UC treatment, offering renewed hope for patients seeking effective and ...

DelveInsight’s “Ulcerative Colitis Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth ...

The European Commission (EC) has granted marketing authorisation for Johnson & Johnson's (J&J) Tremfya (guselkumab) to treat ...

Celltrion, Inc. today announced that six abstracts will be presented at the 2025 Digestive Disease Week® (DDW) Annual Meeting, taking place May 3-6 in San Diego, California. The oral and poster ...

Immunic's lead asset, vidofludimus calcium, shows promise in MS trials, with positive interim results. See why I rate IMUX ...

Upadacitinib showed promising results in achieving clinical and endoscopic remission in people with moderate to severe Crohn ...

Nplate’s cost may depend on factors such as your dosage, whether you have health ... talk with your doctor or insurance provider. Nplate is a biologic drug, which means it’s made from parts ...

Appendectomy may be a useful addition to medical therapy ... using biological agents. Appendectomy alongside standard medical therapy reduced relapse rates in patients with ulcerative colitis ...

It is indicated ... included biologic-naïve patients aged 12 years and older. The studies included patients (136 in Study A and 148 in Study C) who were symptomatic despite the use of antihistamines ...

The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond ... diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease.